Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis

Table 3

Overall adverse events in all treatment strategies.

Adverse events	Constituent ratio
	IVGC	OGC	OIGC	OR	IVGC+OR	OGC + OR	Rtx	Somatostatin	IVIG	Cyclosporine	Teprotumumab
Major event
Liver dysfunction	7/88	0/66	N/A	N/A	1/41	N/A	N/A	N/A	0/21	1/18	N/A
Cushingoid features	7/97	27/156	N/A	0/28	9/49	35/41	N/A	N/A	0/21	0/18	N/A
Weight gain	13/122	39/171	0/14	3/28	4/8	N/A	N/A	N/A	0/21	3/18	N/A
Gastrointestinal	22/138	11/112	1/14	2/28	7/49	4/41	2/13	60/82	0/21	N/A	9/43
Hypertension	5/97	23/181	1/14	0/28	4/49	2/41	N/A	N/A	0/21	6/18	N/A
Hyperglycaemia	11/113	7/145	0/14	N/A	9/41	11/49	N/A	N/A	0/21	0/18	5/43
Inflammatory bowel disease	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	1/43
Escherichia sepsis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	1/43
Urinary retention	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	1/43
Minor event	32/215	23/276	N/A	30/170	21/110	10/41	7/54	N/A	0/21	0/18	32/74